CAI Intl Stock Price, News & Analysis

Caris Life Sciences (NASDAQ: CAI) announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025.

The company will host a conference call and live webcast on November 5 at 3:30 p.m. CT (4:30 p.m. ET) to discuss results. Investors can join the live webcast at https://edge.media-server.com/mmc/p/uwjxydsa. A replay will be available shortly after the call on the Investor Relations section of CarisLifeSciences.com.

Caris Life Sciences (NASDAQ: CAI) will present six collaborative studies at the ESMO Congress 2025 in Berlin, Oct 17-21, 2025. The research, from collaborations with 25+ cancer centers and the Caris Precision Oncology Alliance, spans nine tumor types and uses multiomics (WES, WTS, IHC) and real-world clinico-genomic data to inform subtyping, biomarker discovery and treatment decisions.

Formats include one oral proffered paper, one mini-oral and four posters; full abstracts will be posted on the company website after the event.

Caris Life Sciences (NASDAQ: CAI) has published a validation study in Oncotarget for its FDA-approved MI Cancer Seek® companion diagnostic assay. The test is the first and only FDA-approved solution combining whole exome and whole transcriptome sequencing for solid tumor profiling in both adult and pediatric patients.

MI Cancer Seek demonstrates exceptional performance with 97-100% positive and negative agreement compared to other FDA-approved assays. The test analyzes 228 genes for various mutations, microsatellite instability, tumor mutational burden, and copy number amplification in breast cancer patients. Notably, it enables simultaneous RNA and DNA extraction from minimal tissue input, streamlining the testing process and potentially reducing delays in treatment decisions.

Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for HER2-negative breast cancer treatment. The research analyzed over 4,000 patients to evaluate trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG).

Key findings revealed that T-DXd demonstrated superior effectiveness in hormone receptor (HR)-positive patients, while SG showed better results as first-line treatment for HR-negative and HER2-null tumors. For triple-negative breast cancer patients, both treatments showed comparable benefits, emphasizing the importance of personalized treatment approaches.

Caris Life Sciences (NASDAQ: CAI) reported strong Q2 2025 financial results, with total revenue reaching $181.4 million, up 81.3% year-over-year. The company completed 50,032 clinical therapy selection cases, a 22% increase from Q2 2024. Notable improvements include a gross margin of 62.7% and positive Adjusted EBITDA of $16.7 million.

The company achieved significant milestones, surpassing 900,000+ profiles and 600,000+ total matched profiles. Despite reporting a net loss of $71.8 million (including $37.1 million in one-time IPO-related expenses), Caris generated positive operating cash flow of $7.3 million and free cash flow of $5.9 million.

Looking ahead, Caris projects full-year 2025 revenue between $675-685 million, representing 64-66% growth, with clinical therapy selection volume expected to grow 19-21% compared to 2024.

Caris Life Sciences (NASDAQ: CAI) has published a groundbreaking study in Communications Medicine demonstrating the superior effectiveness of their AI-based image analysis model in predicting cancer biomarkers and patient survival. The study, analyzing data from over 35,000 patients, showed remarkable results in breast cancer patients treated with pembrolizumab, achieving a hazard ratio of 0.511 (p<0.001) compared to 0.882 (p>0.1) for traditional PD-L1 testing methods.

The AI model's analysis of H&E images demonstrated nearly doubled overall survival for AI signature-positive breast cancer patients treated with checkpoint inhibitors. In colorectal cancer, the AI successfully predicted mismatch repair deficiency and microsatellite instability comparable to traditional scoring methods.

Caris Life Sciences (NASDAQ: CAI) has published a groundbreaking study on its enhanced Caris GPSai™ platform in AACR's Cancer Research Communications Journal. The deep learning AI system, trained on over 200,000 cases, demonstrates exceptional accuracy in identifying tumor tissue origin, achieving 95.0% accuracy in non-CUP cases.

The system successfully identified tissue origin in 84.0% of CUP and 96.3% of non-CUP cases during validation across 97,820 cases. In clinical use, GPSai led to diagnosis changes in 704 patients, with 86.1% of cases impacting treatment eligibility based on Level 1 clinical evidence. Notably, 53.6% of surveyed physicians modified treatment plans based on these findings.

Caris Life Sciences (NASDAQ: CAI), an AI TechBio company and precision medicine pioneer, has scheduled its second quarter 2025 financial results announcement for August 12, 2025. The company will host a conference call and webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results. A replay will be available on the company's Investor Relations website after the call.

Caris Life Sciences (NASDAQ: CAI), a precision medicine pioneer, has published significant findings in the New England Journal of Medicine validating research on tumor-infiltrating clonal hematopoiesis (TI-CH). The study analyzed 3,255 matched tumor-blood NGS samples from their database of over 500,000 samples.

Key findings revealed that TI-CH is most prevalent in non-small cell lung cancer (NSCLC), affecting approximately 23% of patients. Notably, patients with TI-CH showed a 30% higher mortality risk. The research addresses the critical challenge of blood-derived mutations being misinterpreted as tumor-specific mutations, which can lead to incorrect treatment decisions.